Clinical Research Directory
Browse clinical research sites, groups, and studies.
Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens
Sponsor: Harvard Medical School (HMS and HSDM)
Summary
This is a multisite prospective cohort study of patients with multidrug- or rifampin-resistant tuberculosis who are treated with an all-oral shortened regimen under routine program conditions in one of three countries (Peru, Lesotho, Kazakhstan).
Official title: Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens Through Improved Epidemiologic Methods
Key Details
Gender
All
Age Range
0 Years - 120 Years
Study Type
OBSERVATIONAL
Enrollment
800
Start Date
2020-09-22
Completion Date
2025-12-31
Last Updated
2024-12-05
Healthy Volunteers
No
Conditions
Interventions
Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)
Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed
Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)
Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed
Bdq, Lzd, Lfx, Z, Dlm (9-12 months)
Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed
Locations (3)
Partners In Health, Kazakhstan
Almaty, Kazakhstan
Partners In Health, Lesotho
Maseru, Lesotho
Socios En Salud
Lima, Lima Province, Peru